Clinical Trial: A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07653100) titled 'A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF' on June 11.

Brief Summary: The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.

Study Start Date: June 22

Study Type: INTERVENTIONAL

Condition: Respiratory Syncytial Virus (RSV)

Intervention: BIOLOGICAL: RSVpreF

RSVpreF Vaccine

BIOLOGICAL: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Pfizer

Published by HT Digital Content Services with permission from Health Daily Digest....